Test Approved to Monitor Levels of Kidney Rejection Drug

Too much of the drug in blood may be toxic

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, Feb. 11, 2011 (HealthDay News) -- A new test to monitor blood levels of a drug used to prevent rejection in kidney transplant patients has been approved by the U.S. Food and Drug Administration.

The Novartis drug Zortress (everolimus) was approved in 2010 to help suppress the immune system and prevent rejection of a transplanted kidney. But if too much of this type of drug -- called an immunosuppressant -- builds up in a patient's blood, it could be toxic, the FDA said in a news release.

The just-approved QMS Everolimus Immunoassay helps doctors monitor blood levels of Zortress, which like other immunosuppressants must be taken by transplant patients for the rest of their lives.

QMS Everolimus is manufactured by Thermofisher, based in Waltham, Mass.

More information

To learn more about this approval, visit the FDA.


Last Updated: